Integrated Treatment of Hepatic Cancer

  • Mengchao Wu
  • Feng Shen
  • Jiamei Yang
  • Weiping Zhou
  • Yiqun Yan
  • Xiaohui Fu


Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with 717,000 new cases reportedly diagnosed in 2007. It is the third most common cause of cancer-related death. It accounts for more than 90% of primary liver cancer. The rates of HCC in men are 2 to 4 times higher than in women. It usually develops between 35 and 65 years of age, when people are most productive and have most family responsibilities. 80%–90% of cases of HCC develop in cirrhotic liver, and cirrhosis is the strongest predisposing factor for HCC (annual incidence rate of 2%–6% in cirrhotic patients). Chronic hepatitis B viral (HBV) infection is the predominant risk factor in Asia and Africa, and chronic hepatitis C viral (HCV) infection in Western countries and Japan. Without proper treatment, the prognosis is very poor and the median survivals for patients with early and advanced tumors are 6–9 months and 1–2 months, respectively. The goal of management is “cancer control”, a reduction in its incidence and mortality as well as an improvement in the quality of life of patients with HCC and their families. This chapter aims to discuss the current therapy algorithm of HCC, focusing on its recent advances.


Hepatocellular Carcinoma Liver Resection Integrate Treatment Portal Vein Tumor Thrombus Small Hepatocellular Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Wu M C, Chen H, Shen F. Surgical treatment of primary liver cancer: report of 5,524 patient. Chin J Surg, 2001, 39: 417–421.Google Scholar
  2. [2]
    Lau W Y, Lai E C, Leung T W, et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg, 2008, 247: 43–48.PubMedCrossRefGoogle Scholar
  3. [3]
    Llovet J M, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48: S20–S37.PubMedCrossRefGoogle Scholar
  4. [4]
    Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology, 2008, 134: 1908–1916.PubMedCrossRefGoogle Scholar
  5. [5]
    Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol, 2007, 4: 424–432.PubMedCrossRefGoogle Scholar
  6. [6]
    Belghiti J, Noun R, Malafosse R, et al. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Ann Surg, 1999, 229: 369–375.PubMedCrossRefGoogle Scholar
  7. [7]
    Rahbari N N, Koch M, Mehrabi A, et al. Portal triad clamping versus vascular exclusion for vascular control during hepatic resection: a systematic review and meta-analysis. J Gastrointest Surg, 2009, 13: 558–568.PubMedCrossRefGoogle Scholar
  8. [8]
    Smyrniotis V, Farantos C, Kostopanagiotou G, et al. Vascular control during hepatectomy: review of methods and results. World J Surg, 2005, 29: 1384–1396.PubMedCrossRefGoogle Scholar
  9. [9]
    Wakai T, Shirai Y, Sakata J, et al. Anatomic resection independently improves long-term survival in patients with T1–T2 hepatocellular carcinoma. Ann Surg Oncol, 2007, 14: 1356–1365.PubMedCrossRefGoogle Scholar
  10. [10]
    Scheele J, Stangl R. Segment-orientated anatomical liver resections. In: Blumgart L H (ed). Surgery of the Liver and Biliary Tract. 3rd edn. Elsevier Science, 2000.Google Scholar
  11. [11]
    Launois B, Jamieson G G. The posterior intrahepatic approach for hepatectomy or removal of segments of the liver. Surg Gynecol Obstet, 1992, 174: 155–158.PubMedGoogle Scholar
  12. [12]
    Castaing D, Emond J, Kunstlinger F, et al. Utility of operative ultrasound in the surgical management of liver tumors. Ann Surg, 1986, 204: 600–605.PubMedCrossRefGoogle Scholar
  13. [13]
    Gagner M, Rheault M, Dubuc J. Laparoscopic partial hepatectomy for liver tumor (abstract). Surg Endosc, 1992, 6: 99.Google Scholar
  14. [14]
    Azagra J S, Goergen M, Gilbart E, et al. Laparoscopic anatomical left lateral segmentectomy-technical aspects. Surg Endosc, 1996, 10: 758–761.PubMedCrossRefGoogle Scholar
  15. [15]
    Figueredo E, Yeung R. Laparoscopic Liver Resection. Medscape J Med, 2008, 10: 68.PubMedGoogle Scholar
  16. [16]
    Lau W Y, Leung T W, Ho S K, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet, 1999, 353: 797–801.PubMedCrossRefGoogle Scholar
  17. [17]
    Partensky C, Sassolas G, Henry L, et al. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg, 2000, 135: 1298–1300.PubMedCrossRefGoogle Scholar
  18. [18]
    Boucher E, Corbinais S, Rolland Y, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology, 2003, 38: 1237–1241.PubMedCrossRefGoogle Scholar
  19. [19]
    Liu C J, Lee P H, Lin D Y, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol, 2009, 50: 958–968.PubMedCrossRefGoogle Scholar
  20. [20]
    Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg, 2009, 96: 975–981.PubMedCrossRefGoogle Scholar
  21. [21]
    Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis, 2009, 41: 36–41.PubMedCrossRefGoogle Scholar
  22. [22]
    Peng B G, Liang L J, He Q, et al. Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol, 2005, 11: 700–704.PubMedGoogle Scholar
  23. [23]
    Lau W Y, Lai E C, Lau S H. The current role of neoadjuvant/adjuvant/ chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int, 2009, 8: 124–133.PubMedGoogle Scholar
  24. [24]
    Wu C C, Cheng S B, Yeh D C, et al. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg, 2009, 96: 1049–1057.PubMedCrossRefGoogle Scholar
  25. [25]
    Choi J W, Park J Y, Ahn S H, et al. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. Am J Clin Oncol, 2009, 32: 564–569.PubMedCrossRefGoogle Scholar
  26. [26]
    Shah S A, Cleary S P, Wei A C, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery, 2007, 141: 330–339.PubMedCrossRefGoogle Scholar
  27. [27]
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996, 334: 693–699.PubMedCrossRefGoogle Scholar
  28. [28]
    Lee K K, Kim D G, Moon I S, et al. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol, 2009, 101: 47–53.CrossRefGoogle Scholar
  29. [29]
    Yao F Y, Ferrell L, Bass N M, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001, 33: 1394–1403.PubMedCrossRefGoogle Scholar
  30. [30]
    Fan J, Yang G S, Fu Z R, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol, 2009, 135: 1403–1412.PubMedCrossRefGoogle Scholar
  31. [31]
    Ravikumar T S, Kaleya R N. Cryotherapy for liver tumors. In: Blumgart L H (ed). Surgery of the Liver and Biliary Tract. 3rd edn. Elsevier Science, 2000.Google Scholar
  32. [32]
    Brown K T, Brody L A. Percutaneous methods for ablation of hepatic tumors. In: Blumgart L H (ed). Surgery of the Liver and Biliary Tract. 3rd edn. Elsevier Science, 2000.Google Scholar
  33. [33]
    Callstrom M R, Charboneau J W. Technologies for ablation of hepatocellular carcinoma. Gastroenterology, 2008, 134: 1831–1835.PubMedCrossRefGoogle Scholar
  34. [34]
    Sugiura N, Takara K, Ohto M O, et al. Percutaneous intratumoral injection of ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma. Acta Hepatol Jpn, 1983, 24: 920.Google Scholar
  35. [35]
    Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol, 1995, 22: 522–526.PubMedCrossRefGoogle Scholar
  36. [36]
    Schoppmeyer K, Weis S, Mössner J, et al. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev, 2009, 8: CD006745.Google Scholar
  37. [37]
    Lau W Y, Lai E C. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg, 2009, 249: 20–25.PubMedCrossRefGoogle Scholar
  38. [38]
    Rossi S, Fornari F, Buscarini L. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J Inter Radio, 1993, 8: 97–103.Google Scholar
  39. [39]
    Cho Y K, Kim J K, Kim M Y, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology, 2009, 49: 453–459.PubMedCrossRefGoogle Scholar
  40. [40]
    Bouza C, López-Cuadrado T, Alcázar R, et al. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol, 2009, 9: 31.PubMedCrossRefGoogle Scholar
  41. [41]
    Hashimoto D, Takami M, Idezuki Y. In-depth radiation therapy by YAG laser for malignant tumors in the liver under ultrasonic imaging (abstract). Gastroenterology, 1995, 88: A1663.Google Scholar
  42. [42]
    Ferrari F S, Megliola A, Scorzelli A, et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. Radiol Med (Torino), 2007, 112: 377–393.CrossRefGoogle Scholar
  43. [43]
    Pacella C M, Francica G, Di Lascio F M, et al. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol, 2009, 27: 2615–2621.PubMedCrossRefGoogle Scholar
  44. [44]
    Lu Z H, Shen F, Yan Z L, et al. Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation. J Cancer Res Clin Oncol, 2009, 135: 783–789.PubMedCrossRefGoogle Scholar
  45. [45]
    Orlacchio A, Bazzocchi G, Pastorelli D, et al. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. Cardiovasc Intervent Radiol, 2008, 31: 587–594.PubMedCrossRefGoogle Scholar
  46. [46]
    Shimizu T, Sakuhara Y, Abo D, et al. Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg, 2009, doi: 10.1007/s00534-009-0124-4Google Scholar
  47. [47]
    Halpern E J. Science to practice: high-intensity focused ultrasound ablation: will image-guided therapy replace conventional surgery? Radiology, 2005, 235: 345–346.PubMedCrossRefGoogle Scholar
  48. [48]
    Wu F, Wang Z B, Chen W Z, et al. Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology, 2005, 235: 659–667.PubMedCrossRefGoogle Scholar
  49. [49]
    Zhang L, Zhu H, Jin C, et al. High-intensity focused ultrasound. HIFU: effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol, 2009, 19: 437–445.PubMedCrossRefGoogle Scholar
  50. [50]
    Li Y Y, Sha W H, Zhou Y J, et al. Short and long term efficacy of high intensity focused ultrasound therapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol, 2007, 22: 2148–2154.PubMedCrossRefGoogle Scholar
  51. [51]
    Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer, 1994, 74: 817–825.PubMedCrossRefGoogle Scholar
  52. [52]
    Ohmoto K, Yoshioka N, Tomiyama Y, et al. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. J Gastroenterol Hepatol, 2009, 24: 223–227.PubMedCrossRefGoogle Scholar
  53. [53]
    Yu Z, Liu W, Fan L, et al. The efficacy and safety of percutaneous microwave coagulation by a new microwave delivery system in large hepatocellular carcinomas: four case studies. Int J Hyperthermia, 2009, 25: 392–398.PubMedCrossRefGoogle Scholar
  54. [54]
    Lau W Y, Yu S C, Lai E C, et al. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg, 2006, 202: 155–168.PubMedCrossRefGoogle Scholar
  55. [55]
    Pleguezuelo M, Marelli L, Misseri M, et al. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther, 2008, 8: 1623–1641.PubMedCrossRefGoogle Scholar
  56. [56]
    Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology, 1987, 163: 345–351.PubMedGoogle Scholar
  57. [57]
    Trevisani F, De Notariis S, Rossi C, et al. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol, 2001, 32: 383–389.PubMedCrossRefGoogle Scholar
  58. [58]
    Bruix J, Sala M, Llovet J M. Chemoembolization for hepatocellular carcinoma. Gastroenterology, 2004, 127: S179–S188.PubMedCrossRefGoogle Scholar
  59. [59]
    Llovet J M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 2003, 37: 429–442.PubMedCrossRefGoogle Scholar
  60. [60]
    Miraglia R, Pietrosi G, Maruzzelli L, et al. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol, 2007, 13: 2952–2955.PubMedCrossRefGoogle Scholar
  61. [61]
    Kawaoka T, Aikata H, Takaki S, et al. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radio, 2009, 132: 687–694.CrossRefGoogle Scholar
  62. [62]
    Li W H, Cheuk E C, Kowk P C, et al. Survival after transarterial embolization for spontaneous ruptured hepatocellular carcinoma. J Hepatobiliary Pancreat Surg,2009, 16: 508–512.PubMedCrossRefGoogle Scholar
  63. [63]
    Meng M B, Cui Y L, Lu Y, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol, 2009, 92: 184–194.PubMedCrossRefGoogle Scholar
  64. [64]
    Shibata T, Isoda H, Hirokawa Y, et al. Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment? Radiology, 2009, 252: 905–913.PubMedCrossRefGoogle Scholar
  65. [65]
    Fan J, Tang Z Y, Yu Y Q, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg, 1998, 15: 674–678.PubMedCrossRefGoogle Scholar
  66. [66]
    Zhou W P, Lai E C, Li A J, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg, 2009, 249: 195–202.PubMedCrossRefGoogle Scholar
  67. [67]
    Peng B G, He Q, Li J P, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg, 2009, 198: 313–318.PubMedCrossRefGoogle Scholar
  68. [68]
    Zhong C, Guo R P, Li J Q, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol, 2009, 135: 1437–1445.PubMedCrossRefGoogle Scholar
  69. [69]
    Hawkins M A, Dawson L A. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer, 2006, 106: 1653–1663.PubMedCrossRefGoogle Scholar
  70. [70]
    Fuss M, Salter B J, Herman T S, et al. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. Gastroenterology, 2004, 127: S206–S217.PubMedCrossRefGoogle Scholar
  71. [71]
    Dawson L A. The evolving role of radiation therapy in hepatocellular carcinoma. Cancer Radiother, 2008, 12: 96–101.PubMedCrossRefGoogle Scholar
  72. [72]
    Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for aged patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys, 2007, 69: 805–812.PubMedCrossRefGoogle Scholar
  73. [73]
    Sugahara S, Oshiro Y, Nakayama H, et al. Proton Beam Therapy for Large Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys, 2009, doi: 10.1016/j.ijrobp.2009.02.030Google Scholar
  74. [74]
    Bal C S, Kumar A. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. Trop Gastroenterol, 2008, 29: 62–70.PubMedGoogle Scholar
  75. [75]
    Sangro B, Bilbao J I, Iñarrairaegui M, et al. Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres. Dig Dis, 2009, 27: 164–169.PubMedCrossRefGoogle Scholar
  76. [76]
    Ibrahim S M, Lewandowski R J, Sato K T, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol, 2008, 14: 1664–1669.PubMedCrossRefGoogle Scholar
  77. [77]
    Kumar A, Srivastava D N, Chau T T, et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment—prospective multicenter clinical trial. Radiology, 2007, 243: 509–519.PubMedCrossRefGoogle Scholar
  78. [78]
    Chen Z N, Mi L, Xu J, et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) Metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys, 2006, 65: 435–444.PubMedCrossRefGoogle Scholar
  79. [79]
    Xu J, Shen Z Y, Chen X G, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology, 2007, 45: 269–276.PubMedCrossRefGoogle Scholar
  80. [80]
    Edeline J, Raoul J L, Vauleon E, et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol, 2009, 15: 713–716.PubMedCrossRefGoogle Scholar
  81. [81]
    Llovet J M, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48: 1312–1327.PubMedCrossRefGoogle Scholar
  82. [82]
    Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology, 2008, 75: S1–S12.CrossRefGoogle Scholar
  83. [83]
    Chow P K, Tai B C, Tan C K, et al. Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology, 2002, 36: 1221–1226.PubMedCrossRefGoogle Scholar
  84. [84]
    Barbare J C, Bouché O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol, 2005, 23: 4338–4346.PubMedCrossRefGoogle Scholar
  85. [85]
    Yu Y, Lang Q, Chen Z, et al. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer, 2009, 115: 5132–5138.PubMedCrossRefGoogle Scholar

Copyright information

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Mengchao Wu
    • 1
  • Feng Shen
    • 1
  • Jiamei Yang
    • 1
  • Weiping Zhou
    • 1
  • Yiqun Yan
    • 1
  • Xiaohui Fu
    • 1
  1. 1.Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations